The Cxbladder sampling system has been developed with the support of leading urologists and nurses to ensure efficiency and ease of use. The process is simple and straightforward.

In Spanish / En Español

Ordering: Customer support teams are on call to answer questions about the test, billing and reimbursement, while sales representatives available for in-office support.

Sample Collection: A complete sampling system is provided for the collection of a patient’s urine. The sampling system contains a proprietary Cxbladder liquid (RNA preservative reagent) to stabilize the patient specimen. Only a small sample of urine is needed and no contact with urine is required.

Shipment and Analysis: The sample is sent to our CLIA-certified and CAP-accredited laboratory for analysis. Pre-paid and pre-labelled packaging is provided, and refrigeration is not required.

Analysis & Reporting: Results will be available within seven working days from sample receipt, and a detailed Cxbladder test report will be delivered securely to your practice.

In-Home Sampling is Now Available for US Patients

To simplify and streamline the bladder cancer testing process, we are now offering Cxbladder in-home sampling for surveillance patients and those presenting with hematuria across the US. Participating patients have the option of submitting their urine sample in the comfort of their own home without the need to physically visit their Urologist, though the kits must be ordered by a Physician.

Phone: 1-855-CXBLADR (1-855-292-5237)
Contact Us for More Information     Download our In-Home Sampling Brochure

Support for Telemedicine & Our In-Sampling Program

1. UroToday Webinar: Alternative Strategies to Deliver Urology Care/ Bladder Cancer Investigation during COVID-19 and Beyond: Video Link

Neal Shore, MD (Medical Director, Carolina Urologic Research Center) leads discussion with Sima Porten, MD (UCSF), and Thomas Nifong, MD, (Pacific Edge Diagnostics USA).

2. Urology Times Webinar: How the COVID-19 Pandemic Impacts Practice Management & Telemedicine: Registration Link

Urology Times' Jonathan Rubenstein, MD, leads discussion with John Gore, MD (University of Washington), Aaron Spitz, MD (University of California), and Eugene Rhee, MD (Kaiser Permanente). Discussion of telemedicine and urinary biomarkers begins 50.52

3. BCAN Patient Webinar: What You Should Know About Covid-19 and Bladder Cancer

Stephanie Chisolm, Director of Education & Research at the Bladder Cancer Advocacy Network (BCAN) leads discussion with Sia Daneshmand, MD (Keck School of Medicine, USC); Professor Sandy Srinivas (Stanford Medicine); and Alec Koo, MD. Cxbladder specific discussion begins 28:12 (part 1), 46:50 (part 2)

 4. Fierce Healthcare Article (23rd Apr): Half of physicians now using telehealth as COVID-19 changes practice operations. Read the article.

 

Last Updated: 16 Apr 2021 02:20 pm